| |
Companion diagnostics play a vital role in oncology therapeutic development, but evolving regulations are changing the game. Join our webinar for expert guidance on adapting your assay development and study design strategies. Register to stay ahead!
|
|
Today’s Big NewsJan 23, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now.
|
|
| By Darren Incorvaia Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. |
|
|
|
By Gabrielle Masson Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. |
By Gabrielle Masson Robert F. Kennedy Jr. said in a letter filed with the U.S. Office of Government Ethics that he will be pulling his investments from two biotechs if he is confirmed to lead the Department of Health and Human Services. |
By Nick Paul Taylor Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival antibody. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now.
|
|
By Nick Paul Taylor Ab&B Bio-Tech has joined the stacked roster of biotechs queuing up to go public in Hong Kong, filing the paperwork for an IPO to fund development of vaccines that could compete with shots from companies including GSK, Merck & Co. and Pfizer. |
By James Waldron A couple of months ago, Exicure was an expiring company with no money or active pipeline. Now, the biotech has acquired the U.S. subsidiary of South Korea’s GPCR Therapeutics along with a clinical-stage blood cancer med. |
By James Waldron An FDA advisory committee may have ruled in elamipretide’s favor back in October, but it looks like Stealth will have to remain patient a while longer before it finally finds out whether the Barth syndrome treatment will get the green light. |
By Gabrielle Masson,Darren Incorvaia The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. |
By Darren Incorvaia Following last year’s launches of several all-in-one CRO offerings, Lindus Health is starting 2025 strong by closing a $55 million series B fundraising round. |
By Zoey Becker More than 80 cases of treatment-associated anaphylaxis have been reported since 1996, according to the FDA's safety notice on Wednesday. The warning also applies to generics, including Sandoz's Glatopa. |
By Angus Liu Incyte CEO Hervé Hoppenot took investors on a whirlwind tour of 18 events that could take place throughout 2025 during his recent presentation at the J.P. Morgan Healthcare Conference. |
By Darren Incorvaia As multisite clinical research corporations proliferate to meet the increased demand for larger, global clinical trials, they’ll have a new trade organization to back them up. The Association of Multisite Research Corporations launched today to represent 14 founding organizations, including Velocity Clinical Research, Javara and Headlands Research. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we explore the trends that defined the industry in 2024 and predict how 2025 might shake out for biopharmas big and small. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
|
|
| Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
